Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 5.00 (3.33%)
Spread: 10.00 (6.667%)
Open: 150.00
High: 155.00
Low: 155.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Fri, 08th Nov 2019 10:30

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - LOSERS

----------

International Consolidated Airlines Group, down 0.5%. The British Airways parent cut its annual earnings per share growth forecast for three years from 2020 to 2022 due to reduced planned capacity growth. The Anglo-Spanish airline holding company now expects average EPS growth of 10% per annum for the three years, compared with 12% per annum estimated previously. IAG attributed the EPS guidance cut to lower planned available seat per kilometre growth, which is now predicted to be 3.4% per annum compared with around 6% per annum estimated previously for 2019 to 2023. Separately, IAG said that October traffic, measured in revenue passenger kilometres, increased by 4.8% to 24.9 million from 23.8 million a year ago. Year-to-date traffic increased 5.6% to 241.6 million revenue passenger kilometres. October capacity, measured in available seat kilometres, increased by 2.7% year-on-year to 29.4 million from 28.6 million. The company carried 10.4 million passengers in October versus 10.0 million a year ago. Load factor increased to 85.0% from 83.3%.

----------

FTSE 250 - WINNERS

----------

Games Workshop, up 14%. The wargames manufacturer and retailer guided for a solid increase in profit and revenue for the first half of its financial year. Games Workshop said its trading to November 3 has remained robust since its last update on September 18, with sales and profit ahead of the same period the year before. Royalties receivable are also significantly ahead of the prior year, driven by the timing of guarantee income on the signing of new licences. As a result, for the six months ending December 2, Games Workshop expects pretax profit to be no less than GBP55 million, and sales to be at least GBP140 million. At the very least, this reflects a 34% rise from GBP40.8 million pretax profit, and 11% from GBP125.2 million in revenue the year before.

----------

Beazley, up 7.6%. The insurer posted a 12% increase in year-to-date gross premiums due to double-digit premium growth across its business, driven by organic growth and rate rises across several business lines. For the nine months to September 30, Beazley recorded gross premiums of USD2.19 billion versus USD1.99 billion a year before. Year-to-date investment return stood at 4.0% versus 0.5%. The company, however, also warned that increased storm insurance claims will hit its 2019 combined ratio, a key profitability measure for insurers. Beazley expects a combined ratio of between 100% and 102% for 2019, assuming normalised claims levels for the remainder of the year. In 2018, the company's combined ratio was 98%. A ratio below 100% indicates that the company is making an underwriting profit, while a ratio above 100% means that it is paying out more money in claims that it is receiving from premiums.

----------

Dunelm, up 3.5%. UBS upped the home furnishings retailer to Buy From Neutral.

----------

Tate & Lyle, up 1.6%. Kepler Cheuvreux raised the supplier of food and beverage ingredients to Hold from Reduce.

----------

FTSE 250 - LOSERS

----------

IMI, down 2.4%. Morgan Stanley reduced the engineer to Equal-Weight from Overweight.

----------

G4S, down 1.5%. RBC chopped the security firm to Perform from Outperform.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

W Resources, up 13%. The tungsten, tin and gold mining company said commissioning and ramp-up activities at La Parrilla continue to advance. Over five tonnes of tungsten concentrate has been produced which will be purified and tin separated next week, W Resources said. Tungsten concentrate production for the T2 phase at La Parrilla will be underway during November. Also, W Resources said it is in advanced stages of finalising finance facilities and additional equity investment from local Spanish investors.

----------

Faron Pharmaceuticals, up 11% at 236.75. The clinical-stage biopharmaceutical company has raised GBP7.5 million through a private placing, which will go towards the clinical development of Clevegen, which is used for cancer treatment by supporting the hosts immune systems against tumours. Faron said it issued 3.9 million shares at a price of 190 pence per share, reflecting a 13% discount to its closing price of 220.00p.

----------

Savannah Petroleum, up 8.9%. The oil and gas company said it has agreed final long-form documentation in relation to Seven Energy International Ltd financial restructuring. In 2017, Savannah agreed to buy an interest in two assets of Seven Energy. As such, Savannah said the procedural transaction completion process has now commenced. As part of this process, a court hearing has been scheduled by the High Court of Justice, Business and Property Courts on Wednesday next week at which Seven Energy will request the appointment of administrators in order to effect the transfer of its assets to the group of companies controlled by Savannah and AIIM.

----------

Aura Energy, up 6.9%. The minerals company has provided Sweden a written notification under Energy Charter Treaty. Uranium in Sweden was banned in August 2018 and Aura Energy is seeking compensation for the financial loss resulting from this decision. In the trigger letter Aura Energy has requested Sweden for amicable settlement. Discussions shall be ended within a three months period, the company said.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Cap-XX, down 11%. The supercapacitors retailer reported pretax loss of USD2.8 million for the year to the end of June compared to USD2.5 million a year prior, as revenue declined to USD3.2 million from USD4.9 million. The major factor underlying this decrease was the last tranche of the "up-front" component of the AVX license being received in financial 2018, Cap-XX said. Over the past twelve months, the company said it has made "good progress" towards achieving its objectives, despite "strong headwinds" from global uncertainty around free trade and the UK's membership of the EU. Looking ahead, Cap-XX said it has entered the current financial year with a strong pipeline of enquiries and a strengthened portfolio of licensing agreements.

----------

Beowulf Mining, down 7.2%. The exploration and development company has raised GBP250,000 in gross proceeds through a share subscription to support Vardar Mineral's Mitrovica and Viti projects in Kosovo and for general working capital purposes. Beowulf said it will issue 4.3 million new ordinary at price 5.75 pence per share. At October 31, the company held GBP1.1 million in cash. The company owns about a 42% stake in Vardar Mineral, which holds exploration licences for the Mitrovica and Viti projects. On Wednesday, Beowulf invested a further GBP100,000 in Vardar Minerals, increasing its ownership to 41.5% from 40.1%.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
13 Mar 2024 11:52

Faron Pharmaceuticals reports year of clinical progress

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.

Read more
6 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Wednesday 13 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Ferrexpo PLCFull Year Results
Gym Group PLCFull Year Results
Hochschild Mining PLCFull Year Results
IP Group PLCFull Year Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Metro Bank Holdings PLCFull Year Results
Nexteq PLCFull Year Results
PensionBee Group PLCFull Year Results
Public Policy Holding Co IncFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Supermarket Income REIT PLCHalf Year Results
Trainline PLCTrading Statement
Vaalco Energy IncFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.

Read more
4 Mar 2024 19:59

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Mar 2024 10:40

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

Read more
27 Feb 2024 21:12

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:26

UK earnings, trading statements calendar - next 7 days

Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Harmony Energy Income Trust PLCFull Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Thursday 29 February 
Cairn Homes PLCFull Year Results
CVS Group PLCFull Year Results
Drax Group PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Haleon PLCFull Year Results
Hammerson PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Hunting PLCFull Year Results
International Biotechnology Trust PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Man Group PLCFull Year Results
Mobico Group PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
Ocado Group PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Schroder Oriental Income Fund LtdFull Year Results
Schroders PLCFull Year Results
Serco Group PLCFull Year Results
Shaftesbury Capital PLCFull Year Results
Spectris PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Vesuvius PLCFull Year Results
Weir Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
19 Feb 2024 11:23

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

Read more
25 Jan 2024 20:09

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:36

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Read more
9 Jan 2024 10:56

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Read more
11 Dec 2023 13:22

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Read more
11 Dec 2023 12:01

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

Read more
7 Dec 2023 19:33

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Read more
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.